{"title":"Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/Virtual","authors":"","doi":"10.1002/jia2.26370","DOIUrl":null,"url":null,"abstract":"<p>Commonly-used Abbreviations 1</p><p>Oral Presentations</p><p>Experience in the Implementation of Long-Acting Treatment 3</p><p>Antiretroviral Treatment Strategies 5</p><p>Infection Prevention 6</p><p>Integrase Strand Transfer Inhibitor (INSTI) Resistance 7</p><p>Co-morbidities and Co-infections 9</p><p>PrEP-ing for the Future 17</p><p>Poster Presentations</p><p>ARV-based prevention—Vertical transmission 20</p><p>ARV-based prevention—PEP 28</p><p>ARV-based prevention—PrEP 29</p><p>Treatment strategies—Novel therapeutic targets (phase I and II) 45</p><p>Treatment strategies—RCTs: Oral and injectable therapy in first line and suppressed switch populations 47</p><p>Treatment strategies—Real-world and implementation science studies oral and injectable therapy 66</p><p>Treatment strategies—Treatment experienced adults (second line and multi-drug resistance studies) 122</p><p>Treatment strategies—Models of care for ageing/frail populations including virological failure and switching 147</p><p>Treatment strategies—Rapid ART initiation 149</p><p>Treatment strategies—Adherence 158</p><p>Clinical management considerations—Women 164</p><p>Clinical management considerations—Late presenters 170</p><p>Clinical management considerations—People who inject drugs (PWID) 180</p><p>Clinical management considerations—Transgender people 181</p><p>Clinical management considerations—Adolescents 182</p><p>Clinical management considerations—Paediatrics 183</p><p>Clinical management considerations—Drug-drug interactions 187</p><p>Cure/post-treatment control 194</p><p>Opportunistic infections and AIDS-defining cancers 200</p><p>Clinical pharmacology 206</p><p>Community-based treatment and prevention initiatives, including primary care screening 209</p><p>Public health strategies including of policy options 219</p><p>Cost and cost-effectiveness 233</p><p>Models of care: evaluation of ARV delivery and coverage 237</p><p>Co-morbidities and complications of disease and/or treatment—Ageing and frailty 245</p><p>Co-morbidities and complications of disease and/or treatment—Cardiovascular/metabolic including weight gain 249</p><p>Co-morbidities and complications of disease and/or treatment—Malignancies: non-AIDS defining 273</p><p>Co-morbidities and complications of disease and/or treatment—Neurological 280</p><p>Co-morbidities and complications of disease and/or treatment—Renal 282</p><p>Co-morbidities and complications of disease and/or treatment—Mental health disorders 287</p><p>Co-morbidities and complications of disease and/or treatment—Other 291</p><p>People living with HIV and COVID-19: Outcomes 304</p><p>People living with HIV and mpox virus 307</p><p>People living with HIV and sexually transmitted diseases 311</p><p>People living with HIV and tuberculosis 320</p><p>People living with HIV and viral hepatitis 323</p><p>People living with HIV and other diseases 329</p><p>Author Index 335</p>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"27 S6","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.26370","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International AIDS Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jia2.26370","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Commonly-used Abbreviations 1
Oral Presentations
Experience in the Implementation of Long-Acting Treatment 3
Antiretroviral Treatment Strategies 5
Infection Prevention 6
Integrase Strand Transfer Inhibitor (INSTI) Resistance 7
Co-morbidities and Co-infections 9
PrEP-ing for the Future 17
Poster Presentations
ARV-based prevention—Vertical transmission 20
ARV-based prevention—PEP 28
ARV-based prevention—PrEP 29
Treatment strategies—Novel therapeutic targets (phase I and II) 45
Treatment strategies—RCTs: Oral and injectable therapy in first line and suppressed switch populations 47
Treatment strategies—Real-world and implementation science studies oral and injectable therapy 66
Treatment strategies—Treatment experienced adults (second line and multi-drug resistance studies) 122
Treatment strategies—Models of care for ageing/frail populations including virological failure and switching 147
期刊介绍：
The Journal of the International AIDS Society (JIAS) is a peer-reviewed and Open Access journal for the generation and dissemination of evidence from a wide range of disciplines: basic and biomedical sciences; behavioural sciences; epidemiology; clinical sciences; health economics and health policy; operations research and implementation sciences; and social sciences and humanities. Submission of HIV research carried out in low- and middle-income countries is strongly encouraged.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
